COT-22 TIMING OF SURGERY AND BEVACIZUMAB THERAPY FOR MALIGNANT GLIOMAS

BACKGROUND: The drug manufacturer recommends postponing initiation of bevacizumab for malignant gliomas at least 4 weeks later postoperatively. Malignant glioma patients with significant neurological deficits due to postoperative residual tumors are preferably needed earlier bevacizumab therapy that...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsubara, Toshio, Mouri, Genshin, Ishigaki, Tomoki, Ikezawa, Munenari, Suzuki, Hidenori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213452/
http://dx.doi.org/10.1093/noajnl/vdz039.202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213452/
http://dx.doi.org/10.1093/noajnl/vdz039.202

Ejemplares similares